Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.

ABSTRACT:

Background

The effects of lumacaftor-ivacaftor therapy on glycemia have not been thoroughly investigated. Continuous glucose monitoring (CGM) provides detailed information about glycemic patterns and detects glucose abnormalities earlier than traditional screening tools for diabetes.

Methods

CGM measures, HbA1c, and oral glucose tolerance test (OGTT) results were collected and within-subject results compared in F508del homozygous youth with CF before and after initiation of lumacaftor-ivacaftor using the Wilcoxon signed-rank test.

Results

Nine youth with CF (6 males, median age 12.7 years) were enrolled. CGM was performed in all participants before (median 26 weeks) and after lumacaftor-ivacaftor (median 29 weeks). HbA1c and fasting plasma glucose increased (p = .02)

SUBMITTER: Li A 

PROVIDER: S-EPMC6342629 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature